Abstract
Biomarkers for preclinical diagnosis of cancer are valuable tools for detection of malignant tumors at early stages in groups at risk and screening healthy people, as well as monitoring disease recurrence after treatment of cancer. However the complexity of the body's response to the pathological processes makes it virtually impossible to evaluate this response to the development of the disease using a single biomarker that is present in the serum at low concentrations. An alternative approach to standard biomarker analysis is called immunosignature. Instead of going after biomarkers themselves this approach rely on the analysis of the humoral immune response to molecular changes associated with the development of pathological processes. It is known that antibodies are produced in response to proteins expressed during cancer development. Accordingly, the changes in antibody repertoire associated with tumor growth can serve as biomarkers of cancer. Immunosignature is a highly sensitive method for antibody repertoire analysis utilizing high density peptide microarrays. In the present review we discuss modern methods for antibody detection, as well as describe the principles and applications of immunosignature in research and clinical practice.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 4833-4837 |
| Number of pages | 5 |
| Journal | Asian Pacific Journal of Cancer Prevention |
| Volume | 16 |
| Issue number | 12 |
| DOIs | |
| State | Published - 2015 |
Keywords
- Antibodies
- Autoantibodies
- Biomarkers
- Cancer
- Diagnostics
- Immunosignature
- Peptide microarray
ASJC Scopus subject areas
- Epidemiology
- Oncology
- Public Health, Environmental and Occupational Health
- Cancer Research